Adalimumab, trade names Humira ("human monoclonal antibody in rheumatoid arthritis") and Exemptia are TNF inhibiting anti-inflammatory drug manufactured by AbbVie and Zydus Cadila respectively. Adalimumab binds to tumor necrosis factor-alpha (TNFα). TNFα normally binds to TNFα receptors, which leads to the inflammatory response of autoimmune diseases. By binding to TNFα, adalimumab reduces this inflammatory response.
| Attributes | Values |
|---|---|
| rdfs:comment |
|
| foaf:depiction | |
| ATC prefix |
|
| ATC suffix |
|
| Bioavailability |
|
| CAS number |
|
| DrugBank |
|
| FDA UNII code |
|
| thumbnail | |
| is product of |